Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02926690 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
A Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by OncoTherapy Science.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT02926690: Recruiting Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by OncoTherapy Science.
NCT02926690 is a Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by OncoTherapy Science. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02926690, a Phase 1 study of Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by OncoTherapy Science.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Conditions Studied
Interventions
- DRUG OTS167PO
Study Locations (8)
New York
- Weill Cornell Medicine | NewYork-Presbyterian - New York
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- Norwalk Hospital - Norwalk
Georgia
- Emory University, Winship Cancer Institute - Atlanta
Hawaii
- Kapi'olani Medical Center for Women & Children - Honolulu
New Hampshire
- Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center - Lebanon
Texas
- MD Anderson Cancer Center - Houston
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-05-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT02926690 shows while recruiting
NCT02926690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which OTS167PO is the first listed.
NCT02926690 lists 8 locations in 7 states (New York, Connecticut, Georgia).
Frequently Asked Questions
What is clinical trial NCT02926690 about?
NCT02926690 is a clinical study titled "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer". The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
What is the current status of trial NCT02926690?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2017-05-29. Estimated completion is 2027-09.
What conditions does trial NCT02926690 study?
This clinical trial studies the following conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02926690?
The interventions under investigation include: OTS167PO (DRUG).
Who is sponsoring clinical trial NCT02926690?
This trial is sponsored by OncoTherapy Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02926690 being conducted?
This trial has 8 study locations across Connecticut, Georgia, Hawaii, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02926690's enrollment target sits among peer trials
70 750th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI